About 75,000 sq. ft. will be available by Q1 ’09, and the remaining 225,000 sq. ft. will be built depending on demand.

Charles River Laboratories reports that it intends to build a new facility in Sherbrooke, Quebec, to support the company’s expanding preclinical services business. The site will provide drug discovery and development services to the pharmaceutical and biopharmaceutical industry.

The new building will be approximately 300,000 sq. ft. The first phase, which is scheduled to open by the first quarter of 2009, will represent approximately 25% of the space and will be dedicated to one or two clients. Charles River says that the remaining construction will be dependent on market demand.

“Our goal was to identify a location similar to Montreal, equally convenient for our customers, where we could situate this new facility,” comments Christopher Perkin, corporate vp and president, Canadian preclinical services. “Sherbrooke is ideal for many reasons, including its proximity to world-class educational institutions offering well-educated laboratory and life sciences graduates as well as opportunities for collaborations and access to cutting-edge technology.”

Previous articleIDM Pharma’s Osteosarcoma Drug Fails to Win FDA Approval
Next articleKineMed to Validate New Drug Applications for Merck KGaA